A new FGFR inhibitor disrupts the TGF‐β1‐induced fibrotic process

Pulmonary fibrosis (PF) is chronic and irreversible damage to the lung characterized by fibroblast activation and matrix deposition. Although recently approved novel anti‐fibrotic agents can improve the lung function and survival of patients with PF, the overall outcomes remain poor. In this study,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of cellular and molecular medicine 2020-01, Vol.24 (1), p.830-840
Hauptverfasser:	Kim, Mi‐Hyoung, Jung, Seung‐Youn, Song, Kyung‐Hee, Park, Jeong‐In, Ahn, Jiyeon, Kim, Eun‐Ho, Park, Jong Kuk, Hwang, Sang‐Gu, Woo, Hee‐Jong, Song, Jie‐Young
Format:	Artikel
Sprache:	eng
Schlagworte:	Actin Akt AKT protein Animals Antibiotics, Antineoplastic - toxicity Antibodies Bleomycin Bleomycin - toxicity Collagen Connective tissue Connective tissue growth factor Connective tissues Enzyme Inhibitors - pharmacology extracellular signal‐regulated kinase 1/2 fibroblast growth factor receptor Fibroblast growth factor receptors Fibroblasts Fibronectin Fibronectins - genetics Fibronectins - metabolism Fibrosis Growth factor receptors Growth factors Imidazoles - chemistry imidazopurine Immunoglobulins Kinases Laboratory animals Lung diseases lung fibrosis Lungs Male Mice Mice, Inbred C57BL Muscles Original Pathogenesis Phosphorylation Pulmonary fibrosis Pulmonary Fibrosis - chemically induced Pulmonary Fibrosis - drug therapy Pulmonary Fibrosis - metabolism Pulmonary Fibrosis - pathology Receptor, Fibroblast Growth Factor, Type 1 - antagonists & inhibitors Receptor, Fibroblast Growth Factor, Type 3 - antagonists & inhibitors Respiratory function Smad protein Smooth muscle Software Transforming Growth Factor beta - genetics Transforming Growth Factor beta - metabolism Transforming growth factor-b1 transforming growth factor‐β
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!